Boston Scientific Extends Option to Acquire EndoTex

Following a second equity investment in the company, Boston Scientific Corp. (Natick, MA, USA) has extended its exclusive option to acquire EndoTex Interventional Systems, Inc. (Cupertino, CA, USA). In addition, Boston Scientific has agreed to acquire EndoTex upon the achievement of certain regulatory milestones. As part of the agreement, EndoTex has extended Boston Scientific's term as its exclusive distributor.

The two companies intend to continue their collaboration in a clinical trial of the EndoTex NexStent carotid stent and Boston Scientific's FilterWire embolic protection device. Interim data from the trial as well as data from other studies have demonstrated that carotid stenting in conjunction with embolic protection may have efficacy comparable to or better than surgical interventions.

"Our assessment of EndoTex's technology suggests that its rolled sheet design provides a novel alternative for clinicians. Adding the NexStent to Boston Scientific's carotid solutions technology portfolio positions Boston Scientific for leadership as the market potentially shifts towards stenting,” said Paul LaViolette, senior vice president and group president, cardiovascular, at Boston Scientific.




Related Links:
Boston Scientific
EndoTex